CJC-1295 is one of the most extensively studied growth hormone-releasing hormone (GHRH) analogues in peptide research, and understanding the distinction between CJC-1295 with DAC and CJC-1295 without DAC (also known as Modified GRF 1-29, or Mod GRF 1-29) is essential for researchers designing accurate in vitro and in vivo experimental models. The addition — or absence — of a Drug Affinity Complex (DAC) fundamentally alters the peptide’s pharmacokinetic profile, changing not only how long it remains active in biological systems but also the pattern of growth hormone (GH) secretion it induces.

Research teams investigating GH axis modulation, pituitary signaling, or GHRH receptor dynamics must account for these structural and functional differences when selecting which variant to employ. This guide breaks down the molecular mechanisms, half-life data, GH pulse pattern differences, and dosing models currently used in published preclinical research and laboratory settings.

Research-only notice: This content is provided for educational discussion and laboratory research purposes only. No medical claims are made or implied. All references to peptide application are strictly within preclinical and in vitro research contexts.

Molecular Structure: What the DAC Modification Actually Does

At its core, CJC-1295 is a tetrasubstituted peptide analogue of GHRH(1-29), modified at four amino acid positions (Ala2→D-Ala, Gln8→Ala, Ala15→Ala, Leu27→Arg) to improve metabolic stability relative to the native hormone. These substitutions protect the peptide from rapid enzymatic degradation by dipeptidyl aminopeptidase IV (DPP-IV) and other plasma proteases — a critical feature for research models involving plasma incubation or in vivo administration.

The DAC modification adds a maleimidoproprionic acid group to the lysine residue at position 30. This reactive group forms a covalent bond with the cysteine-34 position of circulating albumin. Since albumin has an extraordinarily long circulatory half-life (~19 days in humans), binding to it effectively tethers CJC-1295 within the plasma, shielding it from renal filtration and proteolytic breakdown. The result is a dramatic pharmacokinetic shift — from minutes of activity to days.

CJC-1295 without DAC, by contrast, retains only the four amino acid stabilization modifications. It still benefits from improved DPP-IV resistance compared to native GHRH(1-29), but it does not bind albumin and is cleared from the system relatively quickly, producing activity windows measured in hours rather than days.

Half-Life Comparison: Pharmacokinetic Data from Preclinical Studies

The half-life differential between the two CJC-1295 variants is the single most consequential distinction for laboratory dosing model design. Published studies have characterized these pharmacokinetics as follows:

A landmark study by Jetté et al. (2005) published in the Journal of Clinical Endocrinology & Metabolism demonstrated that a single administration of CJC-1295 with DAC in human subjects produced sustained GH and IGF-1 elevations lasting up to 6 days. Mean GH concentrations increased 2–10 fold over baseline. This data established the DAC variant as a powerful tool for researchers interested in prolonged GH axis activation models, though it simultaneously highlighted the absence of physiological pulsatility.

GH Pulse Patterns: Pulsatile vs. Tonic Release in Research Models

Understanding GH secretion patterns is central to interpreting CJC-1295 research data. Under normal physiological conditions, GH is released in discrete pulses — typically 8–12 per day in studied mammalian systems, with a prominent peak during early sleep. These pulses are driven by alternating waves of hypothalamic GHRH and somatostatin (SRIF) activity.

Mod GRF 1-29 (No DAC) and Pulsatile GH Research

Because CJC-1295 without DAC is cleared within approximately 30 minutes of administration, each dose produces a discrete GH release event that closely resembles a natural pulse. Research models using this variant can therefore study individual GH secretion events in relative isolation, examine receptor sensitization/desensitization kinetics at defined intervals, and pair the peptide with ghrelin mimetics at precise time points. This is why the no-DAC variant is the preferred choice in studies modeled after natural pituitary physiology.

As detailed in the CJC-1295 + Ipamorelin stack research overview, combining Mod GRF 1-29 with a ghrelin receptor agonist like Ipamorelin amplifies GH release through two independent pathways — GHRH receptor activation and ghrelin receptor (GHS-R1a) activation — without requiring the long-acting DAC variant. This dual-pathway stimulation approach has produced some of the most consistent pulsatile GH amplification data in preclinical models.

CJC-1295 with DAC and Tonic GH Elevation

The DAC variant sustains GHRH receptor stimulation over days, effectively shifting the GH output pattern from pulsatile to more tonic. Research has observed that this produces a lower-amplitude but persistent elevation in circulating GH and downstream IGF-1, which makes it useful for models where sustained anabolic signaling is the target endpoint rather than the pulse architecture itself.

However, researchers should note that prolonged GHRH receptor stimulation raises the question of receptor downregulation. Studies in rodent models have documented reduced pituitary responsiveness after extended exposure to GHRH analogues — a phenomenon relevant when designing multi-week laboratory protocols using the DAC variant.

The foundational CJC-1295 research overview provides additional context on receptor kinetics and the structural rationale behind both variants for researchers building on these findings.

Laboratory Dosing Models: How Researchers Structure Protocols

Translating pharmacokinetic data into reproducible laboratory dosing models requires careful alignment of administration frequency, dose magnitude, and experimental endpoint. The following section summarizes dosing architectures observed in published research and commonly referenced in preclinical laboratory contexts.

CJC-1295 with DAC — Weekly Administration Models

Given its multi-day half-life, CJC-1295 with DAC is typically administered once weekly in rodent and in vitro research models. Researchers studying IGF-1 production, lean mass accretion, or sustained anabolic signaling pathways have employed this schedule to maintain consistent plasma levels throughout the observation period. The long dosing interval simplifies experimental logistics but makes acute pharmacodynamic measurements (e.g., real-time GH pulse tracking) less feasible.

Studies commonly use dose ranges of 1–2 mcg/kg in rodent models to establish dose-response curves, though researchers should refer to the primary literature when designing specific experimental protocols and adjust for species-specific pharmacokinetic differences.

CJC-1295 without DAC — Pulsatile Administration Models

Research models employing the no-DAC variant typically involve multiple administrations per day to replicate or augment natural GH pulse architecture. In published studies, injection timing has been designed to coincide with established GH trough periods to maximize pituitary responsiveness — a strategy that mirrors how endogenous GHRH release is thought to interact with somatostatin withdrawal cycles.

When paired with Ipamorelin in research, the no-DAC variant is often administered simultaneously, since both peptides act on distinct but synergistic receptor systems. Ipamorelin research on GH pulse studies has demonstrated that this co-administration approach reliably amplifies peak GH concentrations compared to either peptide alone, without the tonic suppression pattern observed with DAC variants.

Receptor Desensitization: A Key Research Variable

One of the most practically significant differences between the two variants in long-duration research models is their relationship to GHRH receptor desensitization. Chronic, uninterrupted GHRH receptor stimulation — as produced by the DAC variant — has been associated in animal studies with reduced receptor density and blunted GH responses over time. This is an important variable for any researcher designing multi-week in vivo protocols.

The no-DAC variant, by contrast, allows for natural recovery periods between GH pulses and is less likely to produce the kind of sustained receptor occupancy that leads to desensitization in these models. Researchers interested in the broader landscape of GH axis modulation may also find it useful to compare CJC-1295 research with Ipamorelin intranasal delivery studies, which address receptor engagement dynamics from the ghrelin pathway perspective.

Choosing Between DAC and No-DAC Variants for Research

Choose CJC-1295 with DAC if…

• Your research objective involves sustained GH or IGF-1 elevation over multi-day observation windows
• Dosing frequency needs to be minimized for logistical or model-design reasons
• You are studying tonic GH signaling effects on lean mass, lipolysis, or downstream anabolic markers
• Your model does not require preservation of natural GH pulse architecture

Choose CJC-1295 without DAC (Mod GRF 1-29) if…

• Your research aims to investigate or replicate pulsatile GH secretion patterns
• You are co-administering a ghrelin mimetic such as Ipamorelin for dual-pathway stimulation studies
• Minimizing receptor desensitization risk over multi-week protocols is a priority
• Your model requires precise, time-locked GH pulse induction at defined intervals
• You are examining acute GHRH receptor pharmacodynamics rather than long-term plasma levels

For researchers exploring the broader context of GH-related peptide stacking, the peptide tier list by mechanism and research depth provides a useful framework for situating CJC-1295 variants alongside other GH-axis compounds.

Research Products for CJC-1295 Laboratory Studies

CJC-1295 with DAC — 5MG Nasal Spray for research →

CJC-1295 No DAC + Ipamorelin — 10MG Nasal Spray for research →

CJC-1295 No DAC + Ipamorelin — 10MG (injectable format) for research →

Ipamorelin — 10MG Nasal Spray for GH pulse research →

Where These Fit in Your Research Library

CJC-1295 variants sit at the intersection of GHRH pharmacology, pituitary signaling, and GH axis modulation — making them foundational tools for any peptide research program focused on growth hormone biology. For researchers building out a comprehensive GH-related peptide library, the following resources are directly relevant:

• CJC-1295 with DAC — 5MG Nasal Spray →
• Ipamorelin — 10MG Nasal Spray →
• CJC + Ipamorelin Combination Stack — 10MG Nasal Spray →

Browse the full SourcePeptides research catalog at sourcepeptides.co →

Summary: CJC-1295 DAC vs No DAC Research Takeaways

The choice between CJC-1295 with DAC and CJC-1295 without DAC is not simply a matter of convenience — it fundamentally defines the GH secretion pattern, receptor engagement dynamics, and dosing architecture of any experimental model. CJC-1295 with DAC offers sustained, albumin-mediated activity lasting approximately 6–8 days, making it well suited for research focused on tonic GH and IGF-1 elevation. CJC-1295 without DAC provides short-acting, pulsatile stimulation that more closely mirrors endogenous GHRH activity, making it the preferred tool for physiological GH rhythm studies and combination protocols with ghrelin mimetics.

Researchers should factor in half-life data, receptor desensitization risks, co-administration compatibility, and endpoint objectives when selecting between these variants. Both have well-established roles in the preclinical literature and continue to be active areas of investigation in GH axis and metabolic research.

Sources & Further Reading

• Jetté L et al. — “Human Growth Hormone-Releasing Factor (hGRF)1-29-Albumin Bioconjugates Activate the GRF Receptor on the Anterior Pituitary in Rats” — Journal of Clinical Endocrinology & Metabolism (2005)
• Teichman SL et al. — “Prolonged Stimulation of Growth Hormone (GH) and Insulin-Like Growth Factor I Secretion by CJC-1295, a Long-Acting Analog of GH-Releasing Hormone, in Healthy Adults” — JCEM (2006)
• Thorner MO et al. — “Growth hormone-releasing hormone and growth hormone-releasing peptide as therapeutic agents” — Lancet (1997)
• PubMed Search — GHRH analogue pulsatile growth hormone research literature
• PubMed Search — CJC-1295 growth hormone research index